Company news
Abeona Therapeutics Inc. news in 2021
Abeona Therapeutics Inc.'s news releases, calls and decks from 2021, newest first.
Abeona Therapeutics Issues Letter to Shareholders
December 21, 2021
Abeona Therapeutics Announces Pricing of Public Offering of Common Stock and Warrants
December 16, 2021
Abeona Therapeutics Announces Public Offering of Common Stock and Warrants
December 15, 2021
Abeona Therapeutics Announces Support of EB Research Partnership's Venture Into Cures Event to Raise Awareness for Education and Research of Epidermolysis Bullosa
November 17, 2021
Abeona Therapeutics Announces Presentation on Pivotal Transpher A Study of ABO-102 in MPS IIIA at the 14th ICIEM Conference
November 16, 2021
Abeona Therapeutics Announces Participation at the Jefferies London Healthcare Conference
November 15, 2021
Abeona Therapeutics Reports Third Quarter Financial Results
November 14, 2021
Abeona Therapeutics to Present at Jefferies Gene Therapy/Editing Summit
October 20, 2021
Abeona Therapeutics Announces Clinical Data Presentations at Upcoming Scientific Congresses
October 12, 2021
Abeona Therapeutics Appoints Gene Therapy Quality Leader Jon Voss as Vice President, Head of Quality
October 11, 2021
Abeona Announces New Chairman, Executive Leadership Promotions and Key Talent Additions for Final Push Towards Two Biologics License Application (BLA) Filings
September 20, 2021
Abeona Therapeutics to Present at Upcoming Investor Conferences
September 6, 2021
Abeona Therapeutics Appoints Edward Carr as Chief Financial Officer
August 9, 2021
Abeona Therapeutics Reports Second Quarter Financial Results
July 27, 2021
Abeona Therapeutics Announces Successful Type B Meeting with U.S. FDA for ABO-102 AAV-based Gene Therapy in Sanfilippo Syndrome Type A (MPS IIIA)
July 27, 2021
Abeona Therapeutics Announces New MRI Data Showing Increased Brain Volume in Young Patients with Sanfilippo Syndrome Type A (MPS IIIA) After Treatment with ABO-102 Gene Therapy
July 25, 2021
Abeona Therapeutics Activates Second Clinical Trial Site in EB-101 Pivotal Phase 3 VIITAL™ Study for Recessive Dystrophic Epidermolysis Bullosa
July 22, 2021
Abeona Therapeutics Announces Updated EB-101 Phase 1/2a Clinical Results in Recessive Dystrophic Epidermolysis Bullosa at the Society for Pediatric Dermatology 46th Annual Meeting
July 6, 2021
Abeona Therapeutics to Present at Jefferies Virtual Healthcare Conference
June 1, 2021
Abeona Therapeutics Issues Letter to Stockholders
May 25, 2021
Abeona Therapeutics Appoints Head of Research & Clinical Development
May 24, 2021
Abeona Therapeutics Reports First Quarter Financial Results
May 17, 2021
Abeona Therapeutics Announces Presentation on New Preclinical Data Supporting the Potential of Cre-Mediated Dual AAV Vector Technology to Enable Delivery of Large Genes Targeted for Treatment of Stargardt Disease at ARVO 2021 Annual Meeting
April 19, 2021
Abeona Therapeutics Appoints Two Industry Leaders as New Independent Members to Its Board of Directors
April 18, 2021
Abeona Therapeutics Announces Appointment of Two New Independent Members to its Board of Directors
March 24, 2021
Abeona Therapeutics Announces 2020 Financial Results and Recent Operational Progress
March 23, 2021
Abeona Therapeutics Announces Appointment of Michael Amoroso as Chief Executive Officer
March 21, 2021
Abeona Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference
February 21, 2021
New Positive Phase 1/2 Interim Data Presented at WORLDSymposium™ Shows Neurocognitive Development of Young MPS IIIA Patients Preserved up to Three Years Following Treatment with Abeona’s ABO-102 Gene Therapy
February 11, 2021
Abeona Therapeutics Announces Clinical Investigator Webinar to Review ABO-102 and ABO-101 Clinical Data Presented at the 17th Annual WORLDSymposium™
February 1, 2021
Abeona Therapeutics Announces Successful Type B Meeting with FDA for Pivotal Phase 3 VIITAL™ Study of EB-101 in Recessive Dystrophic Epidermolysis Bullosa (RDEB)
January 24, 2021